Koa Shoji Holdings (9273) Q3 2025 earnings summary

Executive summary

• Sales and profit increased year-over-year in both the API segment and the manufacture and sales of pharmaceuticals, with profit exceeding plan.

• Net sales for the nine months ended March 31, 2025, rose 5.1% year-over-year to ¥17,620 million, with operating profit up 22.8% to ¥4,381 million and profit attributable to owners of parent up 30.8% to ¥2,959 million.

• Comprehensive income increased 29.5% year-over-year to ¥2,944 million for the nine-month period.

• Operating margin improved by 3.6 percentage points year-over-year.

• Dividend forecast for FYE6/2025 revised upward to 16 yen per share, reflecting strong business performance.

Financial highlights

• Gross profit increased 16.6% to ¥6,002 million; operating profit up 22.8% to ¥4,381 million.

• Ordinary profit grew 23.7% to ¥4,419 million; profit attributable to owners of parent up 30.8% to ¥2,959 million.

• Basic earnings per share for the nine months ended March 31, 2025, was ¥70.27, up from ¥57.10 in the prior year.

• Total assets increased to ¥33,946 million as of March 31, 2025, from ¥32,004 million as of June 30, 2024.

• Equity-to-asset ratio improved to 80.9% from 78.3% at the previous fiscal year-end.

Outlook and guidance

• Full-year FYE6/2025 net sales forecasted to grow 5.5% to ¥23,350 million; operating profit expected to rise 5.4% to ¥4,620 million.

• Profit attributable to owners of parent for the full year is forecast at ¥3,080 million (up 4.5%).

• Basic earnings per share for the full year is projected at ¥73.13.

• Dividend per share forecasted at 16 yen, up from 14 yen in the previous year.

• Facility investments for the year projected to increase 147.3% to ¥3,333 million.